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 Although haemodialysis is an established treatment for patients with end 
stage kidney disease sustaining life for more than 2 million patients world-wide, 
the mortality of dialysis patients remains high, greater than that for some of 
the more common solid organ cancers. As such the question arises as to whether 
more efficient clearance of the waste products of metabolism which accumulate 
would improve outcomes. Recent reports of an association between improved 
patient survivals with higher volume on-line haemodiafiltration exchanges would 
support this hypothesis. This has led to both the development of newer dialyser 
designs based on micro-fluidics using convective clearances to increase middle 
molecule clearances and also a generation of superflux dialysers designed to 
remove larger molecular weight azotaemic toxins which have yet to be studied in 
large randomised prospective clinical trials. However haemodiafiltration and 
superflux dialysers do not affectively clear protein bound azotaemic toxins, and 
there is accumulating evidence that some of these toxins increase 
cardiovascular morbidity and mortality. This has led to resurgence in the 
interest of developing adsorption devices, using activated carbon technology, 
and the development of composite dialyser membranes by either adding carbons 
or other biomaterials to increase adsorption capacity to the standard dialyser. 
 Once anaphylactoid reactions were a recognised complication of 
haemodialysis, however improvements in dialyser membrane bio-incompatibility, 
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and changing sterilisation techniques have markedly reduced these reactions. 
Organic chemicals can leach out from the plastics in the blood lines and dialyser 
and attention is required to adequately rinse the extracorporeal circuit to 
reduce patient exposure. 
 
Introduction 
Advances in dialysis technology have allowed the development of 
haemodialysis services from a treatment limited to a few patients with acute 
kidney injury in one or two centres in highly industrialised countries in the 1940s 
and 1950s, to now a life sustaining treatment for more than two million patients 
with chronic kidney disease worldwide. 
Compared to the original collodion blood tubing and rotating drum 
dialyzer, the current generation of dialysis machines delivering very effective 
small solute clearance represent major technological advances in the delivery of 
dialysis treatments [1]. However despite these technological advances the 
mortality of haemodialysis patients remains high, greater than that for some of 
the more common solid organ cancers. On the positive side, there have been 
advances which have demonstrated benefit to patients, including the 
introduction of modified and synthetic dialyzers for the treatment of patients 
with acute kidney injury [2], and high volume on-line haemodiafiltration 
increasing middle molecule clearances [3]. 
As such there is a pressing clinical need to improve the delivery of 
haemodialysis treatments, to reduce reactions to the extracorporeal circuit and 
improve clearance of azotaemic toxins, to potentially improve patient outcomes.  
 
Improving the design of the extracorporeal circuit 
 As blood passes through the extracorporeal circuit leukocytes, 
monocytes and platelets become activated leading to the release of lipid rich 
microparticles which then accelerate thrombin generation and clotting within 
the extracorporeal circuit. Activation of inflammatory cells can occur both due 
to mechanical stress and also bio-incompatibility of the extracorporeal 
biomaterials. Mechanical stress occurs as blood passes through the vascular 
access, particularly narrow diameter fistula needles, and dialysis catheters, the 
blood pump segment which changes shape with greater pre-pump pressures and 
the dialyzer.  
 Over time the standard blood pump for dialysis circuits changed from a 
small three headed peristaltic rotatory positive displacement pump to the 
current two headed rotary pump. Clinical studies using blood flows < 350 ml/min 
were unable to demonstrate red cell fragmentation, but laboratory studies 
reported increased haemolysis with blood flows increasing above 300 ml/min 
with increasing pre-pump pressures of –150 mmHg [4,5]. This mechanical trauma 
to cells is reduced by using lower pump speeds, but also by redesigning the blood 
pump. Alternative designs include shuttle pumps which combine rotary and piston 
design techniques, with two channels allowing fluids of different physical 
characteristics to be pumped simultaneously, at a half-cycle phase difference,  
by alternatively compressing the two chambers [6]. The advantage of this design 
is that alternating pressure waves across the capillary dialyzer reduces protein 
deposition on the membrane surface, so improving transfer of larger solutes and 
middle molecules [7]. Alternative designs to develop smaller more ergonomically 
efficient blood pumps for dialysis include ripple pump technology, in which a 
series of fingers are aligned on both sides of the blood tubing, and controlled by 
a cam  mounted on a shaft and oriented at different angles so that they 
sequentially activate the fingers to propel blood forward [8]. 
 Most fibrin clot is deposited within the dialyzer, as this represents the 
greatest surface area of the extracorporeal circuit. The choice of anticoagulant 
plays a key role in preventing clot formation with fibrin and platelet deposition 
reduced by changing anticoagulation from unfractionated heparin to low 
molecular weight heparins and then to citrate, however the latter adds 
complexity and costs to standard haemodialysis treatments. Changes in dialyzer 
design to improve blood flow velocity in the outer capillary fibre bundle [9], and 
changing the internal capillary fibre diameter to allow for higher convective 
clearances with haemodiafiltration reduce thrombin generation and micro-
particle generation [10]. Other adaptions have included bonding unfractionated 
heparin to the dialyzer surface, however although initial studies were very 
promising when tested in a randomised prospective multicentre trial was shown 
not to be inferior, rather than superior to intermittent pre-dialyzer saline 
flushes in preventing extracorporeal clot formation to in patients at risk of 
bleeding [11].  
 Clotting within the extracorporeal circuit also occurs at points of 
turbulence in the circuit and also where there is an air-blood interface. As such 
the internal diameter of the blood tubing should be single diameter and “T” 
insertions to the circuit minimised. Similarly the internal surface of the blood 
tubing should be smooth and redundant loops of extracorporeal circuit minimised. 
Fibrin clot is often noted in the venous air detector chamber, and alternative 
designs are now available, dispensing with this section of the extracorporeal 
circuit, replacing this with a section of biocompatible gas permeable plastic 
tubing segment [12]. Some circuit designs have an arterial reservoir chamber in 
which blood is forced upwards and sprays out mixing with air. Redesigning the 
arterial reservoir to make it narrower and so that blood does not spray up and 
mix with air reduces clot formation. Simply introducing heparin bonded plastic 
tubing for the extracorporeal circuit was not shown to substantially reduce clot 
formation and anticoagulant requirements. Newer developments to try and 
reduce clotting have included adding thrombomodulin and complement inhibitors 
to the dialyser surface, but these have not as yet been adopted into clinical 
practice. Vitamin E coating of dialysers have been available for some time, but 
trials of cellulosic dialysers coated with vitamin E have not been convincing in 
demonstrating beneficial effects, although the current trials have generally 
been under powered, and trials of the newer polysulfone dialysers coated with 
vitamin E are awaited. 
 Clot formation within the extracorporeal circuit is dependent upon both 
patient characteristics, in terms of pro-coagulant tendency [13] and then 
activation of inflammatory cells and platelets within the circuit. Cooling reduces 
platelet and leukocyte activation, but until circuits are redesigned to reduce 
leukocyte and platelet activation and minimising blood-air interfaces regional or 
systemic anticoagulation will be required for the majority of patients.  
 
Improving uraemic solute clearances 
 Haemodialysis predominantly removes solutes by diffusion, depending 
upon maintaining a concentration gradient, membrane pore size, membrane 
resistance to solute passage, surface area, surface charge, the distance 
required to diffuse and temperature. Diffusion is more efficient for smaller and 
uncharged solutes with high concentrations in plasma water compared to larger 
and charged solutes, and those bound to plasma proteins and other moieties. 
Convection allows a greater clearance of larger sized solutes, depending on 
relative size compared to membrane pores and plasma water concentration. 
 Although diffusive clearance increases with increasing blood and 
dialysate flows, there comes a point when further increase in velocity no longer 
improves clearances. However simply having high flows does not guarantee 
effective clearances, as blood flow may not be equally distributed between 
central and outer capillary fibres, and similarly dialysate flow may not be equally 
distributed between the capillary fibres. As such manufacturers have adopted 
different designs to improve blood flow and counter-current dialysate flow 
distribution within the dialyzer, by using an inverted pyramid or spiral designs to 
distribute blood flow entering the dialyzer, or introducing an additional vortex 
flow with an “O” ring or external compression using the dialyzer casing, and 
changing dialysate flow patterns by altering the internal baffle angle, depth and 
internal surface length [14] (Figure 1). 
During dialysis and haemodiafiltration proteins are adsorbed onto the 
dialyzer surface, so limiting the effective pore size and restricting the passage 
of larger sized solutes. Although this may reduce some clearances by protein 
“caking” the dialyser membrane surface, the removal of middle molecules in 
clinical practice is similar for both pre and post-dilution haemodiafiltration, due 
to increased membrane protein adsorption in post-dilution mode, whereas in 
theory clearances should be greater for pre-dilution mode.  Some manufacturers 
have deliberately altered dialyser surface membrane charges, or membrane 
composition to increase protein adsorption. Protein deposition can be reduced by 
manufacturing fibres with a wave formation rather than straight fibres, adding 
external mechanical vibration, or by generating cycling pressure waves across 
the dialyzer [7]. 
An alternative approach is to change the dialyzer design from the 
current paradigm of a hollow fibre capillary dialyzer. One such approach is to 
develop membranes designed for high convective transport, similar to a storm 
drain in the street made from a silica nanostructure membrane [12]. Another 
design is to mimic the arterial tree branching into arterioles into capillary 
micro-channels (figure 2). This design has been possible due to the technical 
advances in microfluidics. Applying a pressure across the channels results in a 
controlled convective transport, and haemoconcentration is prevented by re-
infusion of a replacement fluid. The flow pattern within these structures 
minimises activation of leukocytes and platelets so reducing the risk of thrombin 
generation and clot formation. Compared to standard capillary dialyser design at 
which some point along the length of the dialyser capillary the hydrostatic 
pressure gradient across the dialyzer falls so that zero or back filtration occurs, 
these newer designs have constant effective convective clearance along the 
length of the channel. These microfluidic devices need to be stacked to have the 
clearance of current hollow capillary dialyzers. However the convective flow 
from one layer to the one beneath reduces protein deposition on the membranes, 
so preventing protein fouling and reducing the clearance of larger solutes. As 
these channels are very narrow, they become inefficient if microbubbles form. 
Bicarbonate can dissociate to carbon dioxide depending upon pressure and 
temperature. As such these novel designs require pressure monitoring. 
Different research groups have used different membranes ranging from 
polysulphone with polyvinylpyrrolidone (PVP) to polycarbonate. Coating 
polycarbonate micro-channels with polyethylene oxide (PEO)-polybutadiene (PB)-
polyethylene oxide reduces microbubble formation [15]. 
 
Improving azotaemic toxin clearances 
As studies failed to demonstrate an improvement in patient survival with 
greater urea clearance, there has been interest in removing larger solute 
clearances. More recently higher volume on-line haemodiafiltration has been 
suggested to be associated with greater patient survival [3]. The introduction of 
nanotechnology into manufacturing has led to an improvement in the 
standardisation of pore width size and smoothness of the walls of the pores. 
Increasing pore size increases the size of solutes cleared. However there is a 
trade off as larger pores will remove albumin and other larger plasma proteins, 
as with plasma exchange membranes. As such a generation of “super” flux hollow 
fibre capillary dialysers have been produced, which remove free plasma light 
chains, cytokines and other larger solutes (Figure 3). These membranes will allow 
the loss of some albumin, as to achieve a standard pore size of 25-30 kD, some 
pores will be larger. Preliminary trials of these dialyzers have not shown an 
improvement in patient outcomes and trials in patients with acute kidney injury 
due to plasma chain deposition similarly have both shown a benefit. 
However increasing pore size dies not significantly remove protein bound 
azotaemic toxins. There will be some increase, but only in proportion to albumin 
losses. Similarly haemodiafiltration does not increase p-cresyl sulfate (PCS) or 
indoxyl sulfate (IS) clearance [16]. These protein bound toxins have been shown 
in experimental setting to be toxic to the endothelium and heart in animal 
models, and reported in observational studies in haemodialysis patients to be 
associated with increased cardiovascular mortality. However these protein 
bound toxins can be removed by adsorption using activate carbon. Traditional 
activated carbons are microporous which have limited internal penetration by 
proteins, so reducing efficiency of adsorption and also are typically bio-
incompatible. A newer generation of meso-porous carbons allow greater protein 
penetration through channels in the carbons monoliths improving efficiency, and 
also offer improved bio-compatibility characteristics [17]. Microporous carbons 
have little or no absorption for urea, but newer mesorporous are being 
developed which can absorb urea (Figure 4). 
Due to the biocompatibility of carbons an alternative approach has been 
to develop composite dialyser membranes coating the outer surface of the 
standard synthetic hollow fibre membrane with a carbon, which has been shown 
to improve protein bound toxin clearances [18]. However these membranes are 
difficult to manufacture, so others are developing novel biocompatible composite 
membranes comprising a heparin-mimicking polymer brush functionalised carbon 
nanotubes and polyethersulfone (PES), using atom transfer polymerization. In-
vitro testing of these composite membranes showed decreased protein 
adsorption, prolonged clotting times, and suppressed platelet adhesion compared 
to PES membranes, but with greater clearance of uraemic toxins [19].  Other 
options under development include a zeolite–polymer composite nanofiber mesh 
using poly(ethylene-co-vinyl alcohol) (EVOH) as the primary matrix polymer to 
which zeolite nanotubes are incorporated which are capable of selectively 
adsorbing uraemic toxins such as creatinine [20]. 
 
Environmental considerations 
 Single haemodialysis treatments require a large amount of water, as the 
water prepared by reverse osmosis only represents less than 1% of the original 
water intake. Expansion of dialysis services to countries where water is a scare 
resource, and even in highly developed countries saving water is now a priority. 
As such water systems are being developed to recycle rejected water and use 
this as non-drinking domestic water supply and for agricultural usage.  
 Portable and wearable haemodialysis devices require sorbent technology 
to recycle dialysate [6]. However there have been few advances in the 
development of sorbents for dialysis until recently, with most devices using a 
combination of activated carbon with a series of ion exchangers. As conventional 
carbons do not readily adsorb urea, then urea has to be additionally cleared by 
enzymatic or hydrolytic methods. Improvements in adsorption, particularly the 
development of carbons capable of adsorbing urea would potentially allow a new 
generation of adsorbent dialysis devices and reduce the environmental impact of 
current haemodialysis water requirements. 
 There have been advances in polymer technology in terms of reducing the 
use of polyvinyl chloride in the production of the plastics used to manufacture 
the extracorporeal blood tubing, bicarbonate cartridges, containers for acid 
concentrate and general packaging, to provide a newer generation of more 
biodegradable plastics. Similarly testing the integrity of hollow fibre capillary 
dialyzers no longer uses Freon™ which damaged the ozone layer. However if the 
extracorporeal circuit is not adequately rinsed, then organic chemicals can be 
leached from plastics and the dialyser header into the patient, with reports of 
increased nonane, chloroethane, l-butane  and dichlormethane in particular, in 
the exhaled breath of dialysis patients shortly after starting the haemodialysis 
session, and bisphenol-A released into the patient. Dialysers are no longer 
sterilsed with ethylene oxide, but some manufacturers continue to use this 
process to sterilise blood lines. So although anaphlyactoid reactions to dialysis 
are now rare, it is not uncommon for haemodialysis patients to demonstrate a 
mild eosinophilia due to constant exposure to organic chemicals leached from 
the extracorporeal circuit. Alternative methods of sterilisation including 
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 Figure 1 : Schematic diagram of the hollow fibre capillary dialyser 
 
Figure 2 : reduction in plasma free lambda light chains using a superflux dialyser 
(high cut off dialyser HCO) and standard high flux dialyser (Polyflux) 
 
Figure 3 : Microfluidics capillary channel dialyser 
 
Figure 4 : urea clearance with a mesoporous activated carbon monolith 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
